Slide 1: Simulations Plus, Inc. First Quarter Fiscal Year 2009 Conference Call
Exhibit 99.1 Simulations Plus, Inc. NASDAQ: SLP First Quarter Fiscal Year 2009 Conference Call January 15, 2009
Slide 2: Introduction and Welcome
Introduction and Welcome • Introduction and Welcome • Agenda – First Quarter FY 2009 (1QFY09) Financial Summary – Progress in Business Units – Strategy Going Forward – Questions and Answers
Slide 3: Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ si
Slide 4: 1QFY09 Financial Summary
1QFY09 Financial Summary • Gross revenues = $2.133 MM (up 7.5% from 1QFY08) – New record first quarter (first time Q1 over $2 MM) – Pharmaceutical software and services = $1.430 MM (down $8,000 from 1QFY08) • In spite of $260,000 in software license renewals shifted out of Q1 either to Q4 or Q2 – Wo
Slide 5: Share Repurchase Program
Share Repurchase Program • Board of directors authorized share repurchased program for up to $2.5 million from October 2008 through October 2009 • Over 130,000 shares bought back to date at average price per share of about $0.98 – Purpose is to buy back as many shares as possible, not to support a p
Slide 6: Progress - 1
Progress - - 1 • ADMET Predictor™ – Enslein Metabolism Module sales have begun – Collaboration with major pharmaceutical company has developed new Dose Optimization capability to find how much dose would be needed for different new molecules based on mini-GastroPlus simulation within ADMET Predictor
Slide 7: Progress - 2
Progress - - 2 • DDDPlus™ – Sales increasing steadily, with customers now in U.S., Europe, Japan, and India, including two licenses at the FDA – Improvements to the physical models as well as user interface continue at a steady pace – Industry acceptance of this unique new tool appears to be increas
Slide 8: Progress - 3
Progress - - 3 • Words+ subsidiary – New Say-it! SAM™ PDA-based communication system selling well – New Conversa™ communication device selling well – Full-time national sales manager working to improve marketing and sales activities and dealer relationships – Two new employee sales reps added in Cal
Slide 9: Miscellaneous
Miscellaneous • New acquisitions for the pharmaceutical side of the business are undergoing mutual discussions and due diligence visits • Acquisition possibilities for the Words+ subsidiary have not resulted in finding win-win deals - nothing on the table as of today • NIH SBIR Phase II proposal sub
Slide 10: Strategy Going Forward
Strategy Going Forward • Continue to expand product line and services – Pharmaceutical software and services • Expand Life Sciences team by several scientists – For new product development as identified in corporate strategic planning – To increase capacity to conduct consulting studies and funded c
Slide 11: Summary
Summary • Simulations Plus financial strength continues – Excellent cash position – No debt – Share repurchase is gradually reducing number of shares outstanding • Record first quarter for both revenues and earnings – Pharmaceutical software and services revenues almost matched last year even with a
Slide 12: Questions?
Questions? simulationsplus, inc, Of
Slide 13: Slide 13